Fertility startup Inito has raised $29 million in its Series B funding round.
The round was led by Bertelsmann India Investments, with support from existing investor Fireside Ventures.
With this new round, Inito has now raised a total of about $45 million.
The company will use the money to grow its at-home diagnostics platform worldwide. A big focus will be on developing AI-engineered antibodies, which will help create a new generation of advanced home testing kits.
“We forecast how proteins fold in three-dimensional space, design synthetic antibodies using AI, and test millions of variants virtually before creating even one in the lab.”
“A true vision goes beyond adding new tests,” said Inito’s co-founder and CTO Varkun A. Venkateshan in correspondence. “The ultimate goal is to completely rethink diagnostics. If you want to understand what’s happening inside your body at every life stage and health needs, you shouldn’t be limited to clinical visits, lab schedules, or rigid testing systems. You should have the ability to measure, track, and gain insights about your body at home with laboratory confidence.”
These comments were made on the same day that rival Swiggy launched its qualified institutional placement (QIP) to raise around ₹10,000 crore.
This also comes at a time when another competitor, Zepto, has already gone public and is getting ready to raise more funds through an IPO next year.
Read More- RockFlow Raises Tens of Millions to Improve Its AI and Grow Globally
